The Society for the Study of Pain, Nigeria (SSPN) recently endorsed Pfizer's therapeutic pain product, bringing to an end the journey started over two years ago when Pfizer applied and got corporate membership from the association.
A statement by the multinational organisation said this is in a bid to collaborate with SSPN for the overall advancement of pain management in Nigeria. SSPN is an affiliate body of the International Society for the Study of Pain (IASP). The International Association recommends Pfizer's therapeutic pain product as first line for the management of Neuropathic pain.
According to the statement, "the achievement underscored the fact that this product stands in a class of its own as the recommended number one agent for the management of Neuropathic pain."
"Pfizer will continue to strive for continuous improvement in our products, ensuring that our standards are never compromised. We are committed to contributing positively to the communities where we operate and set the standard for quality, safety, and value of medicines."
The statement said the company applies science to its global resources to improve health and well-being at every stage of life and strives to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. "Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, and many of the world's best-known consumer products."
The statement noted that every day, Pfizer works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
"Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.
For more than 150 years, Pfizer has worked to make a difference for all who rely on us," the statement said.